3 more patients treated since April 29.

Efficacy is still improving.  Sounds like a Breakthrough designation winner and a future Standard of Care (SOC).


For all Evaluable Patients, who achieved a CR at 90 days, 88% demonstrate that CR at 180 days, 69% at 270 days, 50% at 360 days and 56% at 450 days, demonstrating a strong duration of complete response.